| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 | — | Subscribe to access the data. | Cell Therapies | Musculoskeletal System | |||
Phase 3 | — | Subscribe to access the data. | Cell Therapies | Musculoskeletal System | |||
Phase 3 | — | Subscribe to access the data. | Cell Therapies | Musculoskeletal System |
Recent Updates
Recently added Catalysts
Artiva Biotherapeutics, Inc.$8.93
-0.89 (-9.23%)
D 32Pipeline Score Richly Valued Biotech · Commercial
Market Cap
194.52 M
EPS
-3.55
P/E Ratio
-
Value Trade
3.46 M
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
19.31 M
Operating CF
-20.95 M
Total Assets
105.95 M
Total Liabilities
18.11 M
Equity
87.85 M
D/E Ratio
12,345
-25.75 %
Week
-37.04 %
1 Month
73.73 %
3 Month
153.87 %
6 Month
-50.81 %
5 Year
-50.81 %
All Time
Cash Data
Cash Position
86.78 M
Monthly Burn
6.98 M
Runway
10.3 mo
Burn Trend
StableSEC Filing
May 8, 2026
Overview
Volume
438.31 K
52 Week Range
1.47 - 14.53
% held by Insiders
37.3 %
% held by Institutions
46.82 %
Enterprise Value
118.00 M
Total Shares
24.52 M
Short %
4.4 %
Float Shares
5.69 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Artiva Biotherapeutics, Inc.
87Total events
5Upcoming
10Tier-1 (high impact)
2024 – 2029Coverage
Upcoming catalysts 2
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆Trial InitiationAlloNKFiledTrial
Subscribe to view catalyst details
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D32
Pipeline Score $22M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 41%
Micro Cap (rank 539 of 912)
Percentile RankArtiva Biotherapeutics, Inc. faces pipeline headwinds (32/100), with $288M risk-adjusted pipeline value, led by Allogeneic NK Cells in Refractory Rheumatoid Arthritis (RA) (Phase 2), across $66B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allogeneic NK Cells Small molecule | Refractory Rheumatoid Arthritis (RA) | Phase 2 | NCT06991114 | 17% | $216M | RECRUITING | 90 | AVERAGE | D (26) | Jan 1, 2029 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AlloNK Fast TrackRMAT | refractory rheumatoid arthritis | Phase 2a | 2026-06-08 | 71% ACR50 response at six months | Artiva Biotherapeutics Highlights AlloNK Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today Read More | |
AlloNK Fast TrackRMAT | refractory rheumatoid arthritis | Phase 2a | 2026-06-08 | 71% ACR50 response at six months | Artiva Biotherapeutics Highlights AlloNK Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today Read More | |
AlloNK Fast TrackRMAT | refractory rheumatoid arthritis | Phase 2a | 2026-06-08 | 71% ACR50 response at six months | Artiva Biotherapeutics Highlights AlloNK Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ARTV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ARTV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ARTVArtiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Artiva Biotherapeutics will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The company is focused on developing AlloNK, a cell therapy for autoimmune diseases, and plans to initiate a Phase 3 trial for refractory rheumatoid arthritis later this year. Initial data suggests promising results for AlloNK in various autoimmune conditions.
Read more →ARTVArtiva Biotherapeutics Highlights AlloNK Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Artiva Biotherapeutics presented promising data for its AlloNK therapy at EULAR 2026, showing significant clinical efficacy in patients with refractory rheumatoid arthritis and other autoimmune diseases. The FDA has granted AlloNK RMAT designation, which supports faster development and review due to its potential effectiveness. The clinical trials reported compelling responses across multiple patient groups, highlighting AlloNK's safety and its capability for outpatient administration. A virtual webcast featuring additional insights into the data will be held today.
Read more →ARTVArtiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Artiva Biotherapeutics announced its participation in the 2026 Jefferies Global Healthcare Conference, scheduled for June 4, 2026. The company will discuss its lead program, AlloNK, which is being evaluated in clinical trials for autoimmune diseases. Artiva plans to initiate a Phase 3 trial for AlloNK in refractory rheumatoid arthritis later this year.
Read more →ARTVSDBJ: Artiva Raises $300M to Fund Phase 3 Trial for RA Cell Therapy
Artiva has raised $300 million to finance a Phase 3 trial for its AlloNK® cell therapy targeting refractory rheumatoid arthritis. The funding aims to advance the company's innovative approach to deep B-cell depletion, which is designed to be scalable and suitable for outpatient settings. This significant investment highlights Artiva's commitment to addressing autoimmune diseases.
Read more →ARTV▼ -7.3%on this news
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Artiva Biotherapeutics has appointed Diego Miralles, M.D., as President and Head of Research and Development. With over 20 years of experience, Dr. Miralles will lead the advancement of AlloNK, a cell therapy for autoimmune diseases, particularly refractory rheumatoid arthritis. The company is preparing for a Phase 3 trial and aims for a BLA submission by 2029.
Read more →ARTV▼ -7.3%on this newsshared move
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
Artiva Biotherapeutics announced multiple data presentations at the EULAR 2026 Congress, showcasing the efficacy of AlloNK in treating rheumatologic diseases. A late-breaking oral presentation highlighted a 71% ACR50 response in refractory rheumatoid arthritis patients. The data suggests AlloNK's clinical responses are comparable to autologous CAR T-cell therapies, with a favorable safety profile.
Read more →ARTV▼ -13%on this news
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Artiva Biotherapeutics has announced the pricing of a $300 million underwritten offering of common stock and pre-funded warrants. The offering includes 23,871,526 shares priced at $11.52 each and is expected to close around May 11, 2026. Proceeds will support the development of their cell therapies for autoimmune diseases, including a Phase 3 trial for AlloNK.
Read more →ARTV▼ -13%on this newsshared move
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Artiva Biotherapeutics reported promising initial clinical data for AlloNK in refractory rheumatoid arthritis, achieving a 71% ACR50 response rate. The company has received FDA alignment for a Phase 3 trial evaluating AlloNK plus rituximab. Despite positive developments, Artiva reported a net loss of $23.5 million for Q1 2026, highlighting ongoing financial challenges.
Read more →ARTV▼ -13%on this newsshared move
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
Artiva Biotherapeutics announced promising initial clinical data for AlloNK in treating refractory rheumatoid arthritis (RA), showing a 71% ACR50 response rate in patients. The FDA has aligned with Artiva on a Phase 3 registrational trial set to begin in 2026, evaluating AlloNK combined with rituximab. The treatment demonstrated a favorable safety profile, with no serious adverse events reported.
Read more →ARTV▼ -7.2%on this news
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Artiva Biotherapeutics, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference where management will engage in a panel and fireside chat. This event is slated for April 15, 2026, and provides an opportunity for Artiva to showcase its clinical-stage biotechnology developments, particularly in cell therapies for autoimmune diseases and cancers. The company is currently evaluating its lead program, AlloNK, in ongoing clinical trials.
Read more →ARTV▲ +6.5%on this news· ran to +25% by day 1
Biotech2050 Podcast: Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms
In a recent Biotech2050 podcast episode, Artiva CEO Fred Aslan discusses the influence of CAR-T therapies on new treatment strategies for autoimmune diseases. He highlights the importance of durable treatment options and how Artiva's AlloNK® platform aims to enhance scalability and patient access. The conversation emphasizes lessons learned from CAR-T that are shaping future approaches.
Read more →ARTV▲ +6.5%on this news· ran to +25% by day 1shared move
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights Initial clinical response data for AlloNK in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food an
Artiva Biotherapeutics announced its financial results for 2025 and highlighted progress with its AlloNK program targeting refractory rheumatoid arthritis (RA). Initial clinical response data for AlloNK is expected in the first half of 2026, with promising results potentially paving the way for a pivotal trial. The company boasts a strong balance sheet with sufficient funds to support operations into mid-2027, despite a reported net loss for the year. Leadership changes and FDA interactions are aimed at advancing the AlloNK program further.
Read more →ARTVArtiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Artiva Biotherapeutics will participate in the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The management team will engage in a fireside chat and meet with investors. Artiva focuses on developing cell therapies for autoimmune diseases and cancers, with ongoing clinical trials for its lead program, AlloNK.
Read more →ARTVArtiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
Artiva Biotherapeutics has appointed Thad Huston as Chief Financial Officer, bringing extensive experience in finance and operations. Huston will support the company's advancement of AlloNK, a promising therapy for autoimmune diseases. The company is also preparing for feedback from the FDA regarding a pivotal trial and plans to share clinical efficacy data soon.
Read more →ARTV▲ +9.2%on this news· ran to +21% by day 3shared move
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
Artiva Biotherapeutics has appointed Elaine Sorg to its Board of Directors, leveraging her extensive experience in the biopharma sector. Her past roles include senior executive positions at leading pharmaceutical companies and expertise in the commercialization of major therapies. The company expresses confidence that Sorg's strategic insight will enhance their efforts to advance the AlloNK cell therapy in clinical trials and facilitate future commercialization aimed at treating autoimmune diseases. This appointment is viewed as a pivotal moment for Artiva as it aims to innovate within the market.
Read more →ARTVBase to Base Biotech Podcast: Natural Killer Cell Therapy
In a recent podcast episode, Lisa Guerrettaz from Artiva Biotherapeutics discusses the challenges of current rheumatoid arthritis treatments and the potential of AlloNK® therapy. The conversation highlights the need for more effective and durable solutions in autoimmune disease management, drawing on lessons from previous therapies and CAR-T insights.
Read more →ARTVArtiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL
Artiva Biotherapeutics announced its participation in the 2026 Transplantation & Cellular Therapy Meetings, where it will present findings on the cost-effectiveness of its AlloNK therapy in rheumatology and its durability in treating Non-Hodgkin Lymphoma. The presentations are scheduled for February 4-7, 2026, in Salt Lake City, Utah. Artiva aims to develop accessible cell therapies for autoimmune diseases and cancers.
Read more →ARTV▲ +10.9%on this news
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
Artiva Biotherapeutics announced positive initial safety and translational data for AlloNK, an allogeneic NK cell therapy, in treating autoimmune diseases. The therapy showed complete B-cell depletion by Day 13 in all patients and was well tolerated in outpatient settings. Artiva plans to engage with the FDA regarding pivotal trial designs for refractory rheumatoid arthritis in 2026.
Read more →ARTV▲ +10.9%on this newsshared move
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Artiva Biotherapeutics reported strong financial results for Q3 2025, highlighting the treatment of over 100 patients with its AlloNK therapy. The company has prioritized refractory rheumatoid arthritis as its lead indication following FDA Fast Track Designation. Initial clinical response data is anticipated in early 2026, with plans for FDA discussions regarding pivotal trial design.
Read more →ARTVArtiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
Artiva Biotherapeutics will host a virtual event on November 12, 2025, to discuss initial safety and translational data for AlloNK in patients with autoimmune diseases. The data indicates a favorable tolerability profile and effective B-cell depletion. The event will include a presentation followed by a Q&A session, inviting both investors and the public.
Read more →ARTV▼ -9.6%on this newsshared move
SDBJ: Artiva Bio Soaring on Focus Shift from Oncology to Autoimmune Disease
Artiva Biotherapeutics is transitioning its focus from oncology to autoimmune diseases, particularly rheumatoid arthritis. The FDA has granted Fast Track Designation for their outpatient treatment, AlloNK®, addressing a significant unmet need in this area. CEO Fred Aslan emphasizes the importance of making effective treatments more accessible to patients.
Read more →ARTV▲ +5.8%on this newsshared move
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
Artiva Biotherapeutics announced its participation in two upcoming investor conferences in November 2025. The events include a virtual fireside chat at TD Cowen's Immunology & Inflammation Summit and a presentation at the Jefferies Global Healthcare Conference in London. The management team will also hold investor meetings, allowing for direct engagement with stakeholders.
Read more →ARTV▲ +117%on this news
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
Artiva Biotherapeutics has prioritized refractory rheumatoid arthritis (RA) as the lead indication for its AlloNK therapy, which has received FDA Fast Track Designation. The company plans to release upcoming data that is expected to demonstrate the therapy's efficacy and safety. AlloNK aims to address the needs of over 100,000 refractory RA patients in the U.S.
Read more →ARTVArtiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
Artiva Biotherapeutics will participate in the Cantor Global Healthcare Conference 2025 on September 3, 2025. The management team will engage in a fireside chat and hold investor meetings. The conference aims to showcase Artiva's commitment to developing effective cell therapies for autoimmune diseases and cancers.
Read more →ARTV▼ -6.8%on this news· ran to -17% by day 3
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights First patient treated in company-sponsored global basket trial exploring AlloNK + rituximab in refractory rheumatoid arthri
Artiva Biotherapeutics reported its financial results for the second quarter of 2025, highlighting significant progress in its clinical trials. The company has initiated a global basket trial with its AlloNK therapy in combination with rituximab for various autoimmune diseases, treating over a dozen patients across multiple sites. The financial stability is supported by $142.4 million in cash, expected to last until Q2 2027. Investors will be looking forward to initial safety and translational data by the end of 2025 and the selection of a lead indication for further development in early 2026.
Read more →ARTVInside Precision Medicine: Asked & Answered with Artiva’s CMO Dr. Subhashis Banerjee
Artiva's CMO, Dr. Subhashis Banerjee, discusses the clinical development of AlloNK® for autoimmune diseases. The company is conducting a Phase 2a basket trial alongside an investigator-initiated study to evaluate safety and efficacy across various conditions. The trials aim to enhance understanding of disease mechanisms and solidify AlloNK® as a versatile immunotherapy option.
Read more →ARTV▲ +6.8%on this newsshared move
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
Artiva Biotherapeutics will participate in the Jefferies Global Healthcare Conference on June 4, 2025. The management team will engage in a fireside chat and hold investor meetings. The company is known for its development of cell therapies aimed at treating autoimmune diseases and cancers, with ongoing clinical trials for its lead program, AlloNK.
Read more →ARTV▼ -11.7%on this news
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
Artiva Biotherapeutics has announced promising longer-term Phase 1/2 data for its AlloNK® therapy combined with rituximab in treating relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy demonstrated a 64% complete response rate and a median duration of response of at least 19.4 months. These results suggest that AlloNK could enhance treatment outcomes for patients who have not responded to previous therapies.
Read more →ARTVArtiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights IND clearance and initiation of global basket trial exploring AlloNK + rituximab in refractory rheumatoid arthritis, Sj gren
Artiva Biotherapeutics reported its first quarter 2025 financial results and highlighted recent advancements, including IND clearance for its AlloNK therapy and the initiation of a global basket trial targeting refractory rheumatoid arthritis and Sjögren's disease. The trial represents a significant milestone as it is the first company-sponsored allogeneic cell therapy trial for these conditions in the U.S. Artiva's cash reserves stand at $166 million, sufficient to support operations through Q2 2027, although the company also reported an increased net loss compared to the previous year. Upcoming presentations at major conferences are expected to unveil initial safety and translational data for AlloNK by the end of 2025.
Read more →ARTVPharmaceutical Manufacturer Q&A: Artiva Allogeneic NK Cell Therapies for Treating Autoimmune Disease
In a recent interview, Artiva CEO Fred Aslan discussed the company's AlloNK® platform, which utilizes natural killer (NK) cell therapies for treating autoimmune diseases. The platform aims to provide scalable and accessible treatments that are better tolerated than traditional autologous therapies. Aslan emphasized the importance of high-yield manufacturing in facilitating outpatient administration.
Read more →ARTVArtiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
Artiva Biotherapeutics announced the upcoming presentation of longer-term Phase 1/2 data for its AlloNK therapy combined with rituximab at the ASGCT 28th Annual Meeting. The data highlights the therapy's prolonged duration of response and deep B-cell depletion, along with a well-tolerated safety profile. In addition, the company will present details regarding the scalability and consistency of the AlloNK manufacturing process during the event, which will take place in New Orleans from May 13-17, 2025.
Read more →ARTV▼ -7.5%on this news· ran to +18% by day 3
GEN: The Body’s Delta Force: Natural Killer Cells Re-Emerge
The article from GEN highlights the resurgence of natural killer (NK) cells as promising candidates for the next generation of immunotherapies. It discusses how advancements in science and technology are enabling cell therapy developers to utilize NK cells beyond oncology, particularly in chronic and autoimmune diseases. Artiva Biotherapeutics is noted for its pioneering work in this area, focusing on safe, scalable, and outpatient-deliverable NK cell therapies.
Read more →ARTV▼ -42%on this newsshared move
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Artiva Biotherapeutics has appointed Dr. Subhashis Banerjee as Chief Medical Officer, who brings over two decades of experience in clinical development of autoimmune diseases. His role will focus on advancing the AlloNK program targeted at B-cell driven autoimmune diseases. The company is confident about leveraging Dr. Banerjee's expertise, alongside a recently strengthened team, to drive innovations in cell therapies. Artiva remains committed to its mission of making effective therapies more accessible to patients.
Read more →ARTV▼ -5.1%on this news· ran to -20% by day 3
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Artiva Biotherapeutics, Inc. will present at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025. The company, based in San Diego, is focused on developing off-the-shelf cell therapies for serious autoimmune diseases and cancers. Their lead product, AlloNK®, is currently undergoing clinical trials for systemic lupus erythematosus. Management will also participate in investor meetings during the conference, aiming to enhance communication with stakeholders.
Read more →ARTV▼ -8.4%on this news
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights Initial data for AlloNK from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK
Artiva Biotherapeutics has released its financial results for the year 2024, highlighting a significant transformation year that included the initiation of dosing for AlloNK in autoimmune disease trials. The company has appointed new leadership with extensive experience in cell therapy and autoimmune indications. Preliminary results from the AlloNK program are anticipated in the first half of 2025. Despite a net loss of $65.4 million compared to a profit in the previous year, Artiva's robust cash position is projected to sustain operations until at least the end of 2026.
Read more →ARTVThe Bio Report Podcast: Turning Natural Killers into Off-the-Shelf Therapies for Autoimmune Disease
The Bio Report podcast features Fred Aslan, CEO of Artiva Biotherapeutics, discussing the advantages of off-the-shelf NK cell therapies. These therapies, part of the innate immune system, offer a safer alternative to CAR-T therapies by avoiding cytokine storms and reducing costs. The potential applications for these therapies extend beyond cancer to autoimmune diseases.
Read more →ARTV▼ -5.7%on this news
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Artiva Biotherapeutics, a clinical-stage biotechnology company focused on cell therapies, has announced its participation in the TD Cowen 45th Annual Health Care Conference scheduled for March 5, 2025, in Boston, MA. Management will present their strategies and will also be available for in-person meetings with investors. The company aims to enhance treatments for autoimmune diseases and cancers, with its lead program currently in clinical trials. A live webcast of the presentation will be available for those unable to attend in person.
Read more →ARTV▼ -5.7%on this news· ran to -24% by day 3
In Vivo: Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm
Artiva Biotherapeutics, led by CEO Fred Aslan, M.D., is pioneering a new direction in cell therapy by utilizing unmodified natural killer (NK) cells. This innovative strategy aims to address oncologic and immune disorders, positioning Artiva as a notable player in the evolving landscape of cell therapy. The company seeks to challenge the established CAR-T therapy paradigm with its unique approach.
Read more →ARTVArtiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.
Artiva Biotherapeutics has appointed Dr. Dan Baker, M.D., to its Board of Directors, enhancing its leadership with his extensive drug development experience. Dr. Baker brings a wealth of knowledge from his tenure in the pharmaceutical industry, particularly in immunology. His involvement is expected to contribute to the advancement of Artiva's AlloNK® program aimed at treating autoimmune diseases. This strategic appointment reflects Artiva's commitment to expanding its expertise and enhancing its therapeutic offerings.
Read more →ARTV▼ -6.6%on this newsshared move
Drug Discovery World: Expanding Access to Cell Therapies for Autoimmune Conditions
The article discusses the challenges and advancements in making cell therapies more accessible for patients with autoimmune diseases and cancer. Fred Aslan, CEO of Artiva Biotherapeutics, emphasizes the need to overcome manufacturing and scalability issues. Despite the potential of these therapies to provide curative treatments, access remains limited due to high costs and side effects.
Read more →ARTVPharmaVoice: Natural Killer Cells, a Rising Alternative to CAR-T Cell Therapy
Natural killer (NK) cells are emerging as a viable alternative to CAR-T cell therapies in oncology and autoimmune diseases. Companies like Artiva Biotherapeutics are exploring NK cells' ability to eliminate cancer cells without the severe side effects associated with T-cell therapies. This approach may also provide a cost-effective, off-the-shelf solution for quicker patient access.
Read more →ARTVCell & Gene The Podcast: The Future of NK Cell Therapy for Autoimmune Disease
Christopher Horan from Artiva Biotherapeutics discusses the benefits of natural killer (NK) cells in autoimmune disease therapy on Cell & Gene: The Podcast. He highlights their safety and efficacy compared to T cells and explains Artiva's innovative manufacturing approach for scalable NK cell production. The conversation emphasizes the potential of NK cells for off-the-shelf therapies.
Read more →ARTVPharmaShots: Enhancing Care with NK Cell Therapy
Fred Aslan from Artiva Biotherapeutics discusses the potential of NK cell therapy in oncology and autoimmune diseases. The interview highlights the promising results of Artiva's AlloNK, an allogeneic NK cell therapy designed to enhance the effects of monoclonal antibodies. Additionally, the funding from Artiva's IPO is being utilized to support ongoing clinical trials.
Read more →ARTVArtiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights • Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing experti
Artiva Biotherapeutics announced its third quarter financial results for 2024, highlighting a robust cash position of $199.6 million and an expansion of its Board with Dr. Alison Moore's appointment. The company is preparing for clinical updates on its lead program, AlloNK, with initial data expected in the first half of 2025 from various autoimmune disease trials. Despite strong financial backing, the loss for the quarter contrasts with previous profitability and highlights challenges ahead, particularly due to the loss of collaboration revenue from Merck. Artiva remains optimistic about its future growth and the potential approval of its therapies.
Read more →ARTVArtiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
Artiva Biotherapeutics, a clinical-stage biotechnology company, will participate in a fireside chat at the Jefferies London Healthcare Conference on November 20, 2024. The event aims to provide insights about the company's innovative therapies for autoimmune diseases and cancers. Investors can attend in-person meetings and listen to a live webcast of the discussion. Artiva's technology focuses on developing effective and accessible cell therapies, with ongoing clinical trials for their AlloNK® therapy.
Read more →ARTVBioProcess Insider: Artiva Discusses Scalable NK Cells to Treat Autoimmune Diseases
Chris Horan, Artiva's Chief Technical Operations Officer, discusses the advantages of allogeneic natural killer (NK) cell therapies over chimeric antigen receptor (CAR)-T therapies. He emphasizes the potential for reduced manufacturing costs and decreased risks associated with NK cell therapies. This insight highlights a promising direction for treating autoimmune diseases.
Read more →ARTV▲ +7.8%on this news
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
Artiva Biotherapeutics has appointed Dr. Alison Moore to its Board of Directors. With over 25 years in the biotechnology industry, she brings substantial expertise, particularly in cell therapy manufacturing. Dr. Moore's experience is expected to support Artiva as it advances its AlloNK® therapy, aimed at treating autoimmune diseases and cancers. The announcement highlights the potential of Artiva's unique manufacturing strategies and clinical trials for these therapies.
Read more →ARTVArtiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
Artiva Biotherapeutics, Inc. will participate in the 2024 Cantor Fitzgerald Global Healthcare Conference on September 18, 2024. The company’s management team will also hold in-person meetings with registered investors at the event. Interested parties can listen to a live webcast of the fireside chat, with a replay available for 90 days afterward. Artiva focuses on developing effective cell therapies for autoimmune diseases and cancers, including their lead therapy AlloNK® currently in clinical trials.
Read more →ARTVArtiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in
Artiva Biotherapeutics reported its financial results for the second quarter of 2024, emphasizing a successful $179 million IPO and progress in its lead program, AlloNK. The company is currently conducting clinical trials for AlloNK, targeting various autoimmune diseases. Despite positive advancements, Artiva continues to face challenges, including increased operating losses and uncertainties in future trial outcomes. The financial results indicate a net loss of $17.8 million, alongside rising operating expenses compared to the prior year.
Read more →ARTVBiotechTV: Checking in with Artiva CEO Fred Aslan after the Company’s $167 Million IPO
Artiva's CEO Fred Aslan discusses the implications of the company's recent $167 million IPO. He emphasizes the potential of their non-modified NK cell therapy platform for treating autoimmune conditions. The funding is expected to enhance their clinical initiatives significantly.
Read more →ARTVArtiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
Artiva Biotherapeutics has announced the pricing of its initial public offering (IPO), upsized to 13,920,000 shares at a price of $12.00 per share. The IPO is expected to raise approximately $167.0 million, aimed at supporting the company's mission to develop cell therapies for autoimmune diseases and cancers. The shares will trade on the Nasdaq under the symbol 'ARTV' from July 19, 2024, with the offering closing on July 22, 2024, pending usual conditions. Major underwriting teams from Jefferies, TD Cowen, and Cantor are managing the offering.
Read more →ARTVPharmaphorum Podcast: Move over CAR-T – the Potential of NK Cells in Cell Therapy
The podcast discusses the potential of natural killer (NK) cells in cell therapy, highlighting their advantages over traditional CAR-T therapies. Dr. Fred Aslan, CEO of Artiva, emphasizes the importance of a strong manufacturing process for NK cell therapies and their application in treating autoimmune diseases. The episode is available on various platforms.
Read more →ARTVCell & Gene: NK Cell Therapies – How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach
Chris Horan, COO of Artiva Biotherapeutics, discusses the potential of NK cell therapies in treating autoimmune diseases and the company's unique manufacturing-first approach. He highlights the challenges faced in developing NK-based therapies and shares insights on cryopreservation practices. Artiva's strategy for clinical trials, which involves multiple doses for patients, is also addressed.
Read more →ARTVBiotechTV: Using NK Cell Therapies for Autoimmune Disease and Cancer with Artiva’s CEO
In a recent interview, Fred Aslan, CEO of Artiva, discussed the company's innovative use of NK cell therapies. These therapies aim to enhance antibody-dependent cellular cytotoxicity, offering potential treatments for autoimmune diseases and cancer. The insights shared underscore the therapeutic promise of these cell therapies.
Read more →ARTVClinical Trials Arena: Artiva Prepares to Kick off Phase I/II Trial for NK Cell Therapy
Artiva Therapeutics is set to begin a Phase I/II trial for its NK cell therapy, AlloNK, targeting lupus nephritis. The company's CEO, Fred Aslan, announced that patient enrollment is ongoing, with plans to dose the first patient by the first half of 2024. This trial represents a significant step in developing innovative treatments for this condition.
Read more →ARTVGEN: Easier Access to NK-Based Cell Therapies
Artiva Biotherapeutics is addressing the challenges of manufacturing time and cost in cell therapies. The company focuses on developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. These therapies are notable for not being genetically modified, potentially increasing patient access.
Read more →ARTVArtiva Named a PM360 2023 Innovative Startup
Artiva has been acknowledged in the 2023 PM360 Innovations Issue for its pioneering work in developing the first allogeneic NK cell therapy aimed at treating lupus nephritis. The company focuses on creating safe and effective cell therapies for patients suffering from severe autoimmune diseases and cancers. Their innovative manufacturing process allows for the production of numerous doses from a single umbilical cord blood unit.
Read more →ARTVBeyond Biotech Podcast: Natural Killer Cells
Artiva Biotherapeutics' CEO, Fred Aslan, discussed key advancements in NK cell therapies on the Beyond Biotech Podcast. The company showcased promising results from two cancer clinical trials and highlighted receiving FDA clearance for an IND for lupus. This marks a significant development in allogeneic NK cell therapies for autoimmune diseases.
Read more →ARTVArtiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies
Exclusive collaboration to assess feasibility and activity of pre-manufactured, co-vialed, cryopreserved, off-the-shelf NK cell combination therapeutics targeting EGFR and additional targets Proof of concept, preclinical assessment to establish activity and feasibility of the co
Read more →Competitive Position
How ARTV ranks across every disease it competes inCompetitive Position is a premium feature
See how ARTV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial